Antithrombotic effect of argatroban on the pial vessels of the rat: a study with He-Ne laser-induced thrombus formation.
The antithrombotic effect of the synthetic thrombin inhibitor (2R,4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfon yl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (argatroban) was investigated in cerebral vessels of the rat. An occlusive thrombus was formed in pial vessels using a He-Ne laser in a closed cranial window technique. Argatroban retarded the formation of thrombi in a dose-dependent manner. The antithrombotic effect of a single intravenous dose of argatroban at 0.5 mg/kg was diminished after 30 min in arterioles and after 50 min in venules, respectively. The antithrombotic activity was maintained, however, by continuous intravenous infusion (2 mg/kg/h).
Sasaki
Y
Y
Laboratory of Physiology, Faculty of Nutrition, Kobe-Gakuin University, Japan.
Morii
S
S
Yamashita
T
T
Yamamoto
J
J
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives; D001160:Arterioles / Q000293:injuries; D001241:Aspirin / Q000627:therapeutic use; D003399:Craniotomy / Q000379:methods; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006371:Helium; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D002542:Intracranial Embolism and Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D007834:Lasers / Q000009:adverse effects*; D009356:Neon; D010841:Pia Mater / Q000098:blood supply* / Q000293:injuries; D010875:Pipecolic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides; D013988:Ticlopidine / Q000627:therapeutic use; D014699:Venules / Q000293:injuries
D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D013449:Sulfonamides; D006371:Helium; D009356:Neon; D001120:Arginine; C031942:argatroban; D013988:Ticlopidine; D001241:Aspirin